Abstract | PURPOSE: METHODS: Direct binding and uptake of radiolabeled folates and anti-folates and the assessments of drug concentration of drug that inhibited cell growth 50 % (IC(50)) in vitro in the presence or absence of antibody. RESULTS: CONCLUSIONS:
Farletuzumab does not block FRα binding of folates and anti-folates, minimally retards folate delivery via FRα-mediated transport, and minimally retards the growth of cells in vitro. Concomitant use of farletuzumab and pemetrexed is not contraindicated.
|
Authors | B A Kamen, A K Smith |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 70
Issue 1
Pg. 113-20
(Jul 2012)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 22644798
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Folate Receptor 1
- Glutamates
- Tetrahydrofolates
- Pemetrexed
- Tritium
- farletuzumab
- Guanine
- Folic Acid
- 5-methyltetrahydrofolate
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(pharmacology)
- Binding, Competitive
(drug effects)
- CHO Cells
- Cell Line
- Cell Line, Tumor
- Cell Membrane
(drug effects, metabolism)
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Cricetinae
- Cricetulus
- Dose-Response Relationship, Drug
- Folate Receptor 1
(antagonists & inhibitors, metabolism)
- Folic Acid
(metabolism, pharmacology)
- Glutamates
(metabolism, pharmacology)
- Guanine
(analogs & derivatives, metabolism, pharmacology)
- Humans
- Kinetics
- Pemetrexed
- Tetrahydrofolates
(metabolism, pharmacology)
- Tritium
|